Search

Displaying results 2471 - 2480 of 3732 in total
  1. Drug

    Rifamycin

    go.drugbank.com/drugs/DB11753
    ApprovedInvestigationalWithdrawn

    Rifamycin is the prime member of the rifamycin family which are represented by drugs that are a product of fermentation from the gram-positive bacterium Amycolatopsis mediterranei, also known as Streptomyces mediterranei. The parent comp...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  2. Drug

    Talinolol

    go.drugbank.com/drugs/DB11770
    Investigational

    Talinolol has been investigated for the basic science of Gastrointestinal Motility Disorder.

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  3. Drug

    Pazufloxacin

    go.drugbank.com/drugs/DB11774
    Investigational

    Pazufloxacin is under investigation in clinical trial NCT02592096 (Pazufloxacin Mesilate Ear Drops Clinical Trial Protocol).

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  4. Drug

    Danoprevir

    go.drugbank.com/drugs/DB11779
    Investigational

    Danoprevir has been used in trials studying the treatment of Hepatitis C, Chronic.

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors
  5. Drug

    Allicin

    go.drugbank.com/drugs/DB11780
    Investigational

    Allicin has been used in trials studying the treatment of Follicular Lymphoma.

    Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP3A Inhibitors
  6. Drug

    Esketamine

    go.drugbank.com/drugs/DB11823
    ApprovedInvestigational

    Major depressive disorder (MDD) is a significant cause of disability worldwide and the most common illness preceding suicide. On March 5, 2019, the nasal spray drug, esketamine, also known as Spravato (by Janssen Pharmaceuticals), was ap...

    Categories: NMDA Receptor Antagonists, Non-Competitive N-Methyl D-Aspartate (NMDA) Receptor Antagonists
  7. Drug

    Relugolix

    go.drugbank.com/drugs/DB11853
    ApprovedInvestigational

    Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. … [A225761] Relugolix is the first (and currently only) orally-administered GnRH receptor antagonist approved for the treatment of prostate cancer - similar therapies such as [degarelix] require subcutaneous

    Categories: Gonadotropin Releasing Hormone Receptor Antagonists, P-glycoprotein inhibitors
  8. Drug

    Valspodar

    go.drugbank.com/drugs/DB11869
    Investigational

    Valspodar has been used in trials studying the treatment of Cancer, Sarcoma, Leukemia, Lymphoma, and Breast Cancer, among others.

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  9. Drug

    Tetramethrin

    go.drugbank.com/drugs/DB13752
    Experimental

    Categories: P-glycoprotein inhibitors
  10. Drug

    Epanolol

    go.drugbank.com/drugs/DB13757
    Experimental

    Epanolol is an beta blocker.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Substrates